
This article is for educational and informational purposes only. The peptides discussed are not approved by the FDA or any equivalent regulatory authority for human use. No established human dosing protocols, GMP purity standards, or long-term safety data exist for most compounds mentioned. Content reflects current research literature, not medical advice. Do not use any research compound without consulting a licensed healthcare professional.
Sleep tracking, cold exposure, intermittent fasting, red light therapy
NMN, NAD+, creatine, omega-3, berberine, ashwagandha
CJC-1295, BPC-157, rapamycin, semaglutide, semax
Mechanism: GH-releasing hormone analogue + ghrelin mimetic โ amplifies natural GH pulsatility
Status: Phase II trials (as individual agents)
Mechanism: Angiogenesis promotion, tendon collagen remodeling, nitric oxide pathway activation
Status: Preclinical (animal models)
Mechanism: Actin polymerization regulation, satellite cell migration, anti-inflammatory signaling
Status: Preclinical / early human wound research
Mechanism: ACTH(4-7) analogue โ upregulates BDNF, VEGF; dopamine/serotonin modulation in frontal cortex
Status: Approved in Russia (nasal drops); preclinical in West
Mechanism: Tuftsin analogue โ anxiolytic, GABA-A modulation, focus enhancement without sedation
Status: Approved in Russia; research-only elsewhere
Mechanism: HGF/MET agonist โ synapse formation; reported ~10 millionร more potent than BDNF in some in vitro models
Status: Preclinical (Washington State Univ. research)
Mechanism: Neuroprotective; dopaminergic & serotonergic modulation in CNS injury models
Status: Preclinical
Mechanism: Amplifies nocturnal GH pulse that occurs during deep sleep; syncs GH with circadian rhythm
Status: Phase II trials
Mechanism: Hypothalamic nonapeptide; increases slow-wave (delta) sleep amplitude in animal models
Status: Preclinical; small human studies (1970sโ90s)
Mechanism: Pineal gland tetrapeptide; stimulates melatonin synthesis and circadian normalization
Status: Preclinical; Russian clinical studies (limited)
Mechanism: Telomerase activation in somatic cells; melatonin regulation; anti-oxidant pathway upregulation
Status: Preclinical / limited Russian trials
Mechanism: Thymic peptide; T-cell maturation, NK cell activation, immune senescence reversal
Status: FDA-approved (Zadaxin) for hepatitis B/C in some markets
Mechanism: Copper tripeptide; activates 4,000+ genes; collagen synthesis, anti-inflammatory, SOD upregulation
Status: OTC cosmetic; systemic use preclinical
Mechanism: Mitochondrial-derived peptide; AMPK activation, metabolic flexibility, cellular stress resilience
Status: Preclinical; active research (USC/Mayo Clinic)
Mechanism: VEGF upregulation, angiogenesis, collagen scaffold formation in tendons and muscle fascia
Status: Preclinical
Mechanism: Thymosin ฮฒ4 C-terminal fragment; actin regulation, stem cell mobilization, wound closure acceleration
Status: Preclinical / early wound care data
Mechanism: Fibroblast activation, matrix metalloproteinase modulation, anti-inflammatory cytokine reduction
Status: Topical: extensive clinical data; systemic: preclinical
Research chemical vendors operate outside pharmaceutical GMP standards. Third-party testing is rare. Independent analyses have found incorrect concentrations, wrong compounds, and contamination with bacterial endotoxins in popular peptide products.
Animal model dosing doesn't translate directly to humans due to differences in body weight, metabolism, and receptor density. No established human dosing guidelines exist for most research peptides. Online 'protocol' communities are essentially crowd-sourcing dose-finding experiments.
Peptides affecting GH axis, immune function, or neurotransmitter systems can have complex interactions with medications and underlying health conditions. GH secretagogues, for example, are contraindicated in active malignancy due to potential proliferative effects.
Legal to purchase as research chemicals in most jurisdictions, but not for human use. Regulatory enforcement is inconsistent. Some peptides have been banned from sports (WADA list includes BPC-157, TB-500, GHRPs). Customs regulations vary by country.
Clinical endocrinology research (NIH-funded)
GHRH analogues + GHRP combinations studied for GH deficiency in aging adults. Merriam et al. demonstrated restored GH pulsatility in a Phase II trial using a GHRH analogue โ the mechanistic foundation for CJC-1295/Ipamorelin combination protocols used in anti-aging clinics.
Oncology & infectious disease clinical trials
Tฮฑ1 (Zadaxin) has regulatory approval in multiple countries for hepatitis B/C and as an immune adjuvant. Its use as a 'longevity' and immune optimization compound in biohacking is an extrapolation from approved indications โ though the underlying biology (T-cell maturation, NK activation) is well-documented.
Russian Academy of Medical Sciences
Semax is approved in Russia as a nasal spray for ischemic stroke, cognitive impairment, and ADHD. Its BDNF-upregulating mechanism has been studied extensively in Russian clinical literature since the 1980s. Western biohackers are essentially accessing a compound with a legitimate clinical history in another regulatory system.
University of Southern California / Mayo Clinic
MOTS-c was identified as a mitochondria-derived peptide by Lee et al. (2015) at USC. Ongoing research explores its role as an exercise mimetic, AMPK activator, and potential treatment for metabolic syndrome. It sits at the cutting edge of longevity biology โ interesting science, but far from clinical application.
Biohacking is a broad term for using data, technology, lifestyle interventions, and biological compounds to optimize human performance, health span, and cognitive function. Peptides have become central to the biohacking conversation because they are highly targeted molecular signals โ unlike broad-spectrum drugs, a peptide can be designed to interact with a very specific receptor or pathway. For biohackers interested in GH regulation, tissue repair, or cognitive enhancement, peptides offer apparent specificity that appeals to the optimization mindset.
In most jurisdictions (including the US), unscheduled peptides like BPC-157, TB-500, and Epithalon are legal to purchase as 'research chemicals' for laboratory research purposes. They are NOT approved for human use, and selling or marketing them for human consumption is illegal in the US under FDA regulations. The legal grey zone means they are widely available online, but buyers accept substantial uncertainty about purity, dosing accuracy, and long-term safety.
It varies enormously by peptide. Some โ like CJC-1295/Ipamorelin and Thymosin Alpha-1 โ have legitimate Phase II clinical trial data. Others like BPC-157 and TB-500 have strong animal model evidence but zero human RCTs. Still others like Dihexa are very early-stage with exciting preclinical data but no established safety profile in humans. The biohacking community often moves faster than the clinical trial pipeline, which is precisely why the risk-evidence gap matters so much.
Peter Attia has discussed growth hormone secretagogues (like ipamorelin/CJC-1295) in the context of GH optimization in his Longevity community. Bryan Johnson's Blueprint protocol focuses more on rapamycin, NMN, metformin, and lifestyle biomarkers โ his peptide use is less publicly documented. The broader longevity medicine community (Attia, Huberman, Rhonda Patrick) tends to discuss peptides cautiously, usually within supervised clinical settings, which is different from DIY biohacking.
The most responsible path is to work with a licensed physician โ ideally one specializing in functional, anti-aging, or sports medicine โ who can order lab work to establish baselines, help select compounds with the best evidence-to-risk ratio, source from GMP-verified compounding pharmacies, and monitor for adverse responses. Self-sourcing from unknown research chemical vendors carries real risk of contamination, incorrect concentrations, or completely different compounds. Education, bloodwork, and medical oversight are the pillars of responsible self-experimentation.
| Author(s) | Year | Journal | Key Findings |
|---|---|---|---|
| Sikiric et al. | 2024 | Current Neuropharmacology | BPC-157 multi-system effects: angiogenesis, neuroprotection, and GI cytoprotection in animal models |
| Goldstein et al. | 2023 | Journal of Translational Medicine | Thymosin ฮฒ4 (TB-500) promotes actin polymerization and wound closure in preclinical models |
| Khavinson et al. | 2022 | Frontiers in Endocrinology | Epithalon (Epithalamin) activates telomerase and normalizes melatonin production in aging models |
| Picciotto & Bhide | 2023 | Neuropsychopharmacology | Dihexa exhibits HGF/MET agonism; potent synaptogenic activity in hippocampal cell cultures |
| Kim et al. | 2024 | Cell Metabolism | MOTS-c as mitochondria-derived peptide regulates AMPK pathway and improves metabolic flexibility |
| Pickart & Margolina | 2018 | Biomolecules | GHK-Cu activates 4,000+ human genes; broad anti-aging and wound-healing effects confirmed topically |
| Merriam et al. | 2001 | J. Clinical Endocrinology & Metabolism | GHRH analogues (CJC-1295 precursor) restore GH pulsatility in older adults in Phase II trial |